Макрофаги, ассоциированные с опухолью: современное состояние исследований и перспективы клинического использования

Обложка

Цитировать

Полный текст

Об авторах

А. Н. Грачев

НИИ канцерогенеза, ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России

Автор, ответственный за переписку.
Email: alexei.gratchev@gmail.com
ORCID iD: 0000-0003-2137-1866

Алексей Николаевич Грачев.

115478 Москва, Каширское шоссе, 24

Россия

Д. В. Самойлова

НИИ канцерогенеза, ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России

Email: fake@neicon.ru
ORCID iD: 0000-0001-5639-0835

115478 Москва, Каширское шоссе, 24

Россия

М. А. Рашидова

НИИ канцерогенеза, ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России

Email: fake@neicon.ru

115478 Москва, Каширское шоссе, 24

Россия

А. А. Петренко

НИИ канцерогенеза, ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России

Email: fake@neicon.ru
ORCID iD: 0000-0001-6951-3996

115478 Москва, Каширское шоссе, 24

Россия

О. В. Ковалева

НИИ канцерогенеза, ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России

Email: fake@neicon.ru
ORCID iD: 0000-0001-6132-9924

115478 Москва, Каширское шоссе, 24

Россия

Список литературы

  1. Fernandez-Velasco M., Gonzalez-Ra- mos S., Bosca L. Involvement of monocytes/macrophages as key factors in the development and progression of cardiovascular diseases. Biochem J 2014;458(2):187–93. doi: 10.1042/BJ20131501. PMID: 24524191.
  2. Chavez-Sanchez L., Espinosa-Luna J.E., Chavez-Rueda K. et al. Innate immune system cells in atherosclerosis. Arch Med Res 2014;45(1):1–14. doi: 10.1016/j.arcmed.2013.11.007. PMID: 24326322.
  3. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5(12):953–64. DOI: 10.1038/ nri1733. PMID: 16322748.
  4. Gratchev A., Kzhyshkowska J., Kothe K. et al. Mphi1 and Mphi2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals. Immunobiology 2006;211(6–8):473–86. doi: 10.1016/j.imbio.2006.05.017. PMID: 16920487.
  5. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352(16):1685–95. doi: 10.1056/NEJMra043430. PMID: 15843671.
  6. Bingle L., Brown N.J., Lewis C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002;196(3):254–65. doi: 10.1002/path.1027. PMID: 11857487.
  7. Stout R.D., Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol 2004;76(3):509–13. doi: 10.1189/jlb.0504272. PMID: PMC1201486.
  8. Stein M., Keshav S., Harris N., Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992;176(1):287–92. PMID: 1613462.
  9. Locati M., Mantovani A., Sica A. Macrophage activation and polarization as an adaptive component of innate immunity. Adv Immunol 2013;120:163–84. doi: 10.1016/B978-0-12-4170285.00006-5. PMID: 24070384.
  10. Gratchev A., Schledzewski K., Guillot P., Goerdt S. Alternatively activated antigenpresenting cells: molecular repertoire, immune regulation, and healing. Skin Pharmacol Appl Skin Physiol 2001;14(5):272–9. doi: 10.1159/000056357. PMID: 11586068.
  11. Mantovani A. Chemokines in neoplastic progression. Semin Cancer Biol 2004;14(3):147–8. doi: 10.1016/j.semcancer.2003.10.010. PMID: 15246048.
  12. Ferreira M.A. Cytokine expression in allergic inflammation: systematic review of in vivo challenge studies. Mediators Inflamm 2003;12(5):259–67. doi: 10.1080/09629350310001619717. PMID: 14760932.
  13. Goerdt S., Politz O., Schledzewski K. et al. Alternative versus classical activation of macrophages. Pathobiology 1999; 67(5–6):222–6. doi: 10.1159/000028096. PMID: 10725788.
  14. Gordon S., Clarke S., Greaves D. et al. Molecular immunobiology of macrophages: recent progress. Curr Opin Immunol 1995;7(1):24–33. PMID: 7772278.
  15. Gratchev A., Kzhyshkowska J., Utikal J., Goerdt S. Interleukin-4 and dexamethasone counterregulate extracellular matrix remodelling and phagocytosis in type-2 macrophages. Scand J Immunol 2005;61(1):10–7. doi: 10.1111/j.0300-9475.2005.01524.x. PMID: 15644118.
  16. Gratchev A., Guillot P., Hakiy N. et al. Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3. Scand J Immunol 2001;53(4):386–92. PMID: 11285119.
  17. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3(1):23–35. doi: 10.1038/nri978. PMID: 12511873.
  18. Gratchev A., Kzhyshkowska J., Kannookadan S., et al. Activation of a TGF-betaspecific multistep gene expression program in mature macrophages requires glucocorticoid-mediated surface expression of TGF-beta receptor II. J Immunol. 2008;180(10):6553–65.
  19. Gratchev A. TGF-beta signalling in tumour associated macrophages. Immunobiology 2017;222(1):75–81. doi: 10.1016/j.imbio.2015.11.016.
  20. Anderson C.F., Gerber J.S., Mosser D.M. Modulating macrophage function with IgG immune complexes. J Endotoxin Res.2002;8(6):477–81. doi: 10.1179/096805102125001118. PMID: 12697094.
  21. Herrero C., Hu X., Li W.P. et al. Reprogramming of IL-10 activity and signaling by INF-γ. J Immunol 2003;171(10): 5034–41. PMID: 14607900.
  22. Kim J., Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 2009;37(12):1445–53. doi: 10.1016/j.exphem.2009.09.004. PMID: 19772890.
  23. Chevrier S., Levine J.H., Zanotelli V.R.T. et al. An immune atlas of clear cell renal cell carcinoma. Cell 2017;169(4):736–49. e18. doi: 10.1016/j.cell.2017.04.016. PMID: 28475899.
  24. Blaser M.J., Perez-Perez G.I., Kleanthous H. et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995;55(10):2111–5. PMID: 7743510.
  25. Kuper H., Adami H.O., Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 2000;248(3):171–83. PMID: 10971784.
  26. Scholl S.M., Pallud C., Beuvon F. et al. Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 1994;86(2):120–6. PMID: 8271294.
  27. Shacter E., Weitzman S.A. Chronic inflammation and cancer. Oncology (WillistonPark) 2002;16(2):217–26.
  28. Maeda H., Akaike T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Mosc) 1998;63(7):854–65. PMID: 9721338.
  29. Yamanishi Y., Boyle D.L., Rosengren S. et al. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 2002;99(15):10025– 30. doi: 10.1073/pnas.152333199. PMID: 12119414.
  30. Ernst P.B., Gold B.D. The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu Rev Microbiol 2000;54:615–40. PMID: 11018139.
  31. Hudson J.D., Shoaibi M.A., Maestro R. et al. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 1999;190(10):1375–82. PMID: 10562313.
  32. Brigati C., Noonan D.M., Albini A., Benelli R. Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis 2002;19(3):247–58. PMID: 12067205.
  33. Leek R.D., Harris A.L. Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 2002;7(2):177–89. PMID: 12463738.
  34. Saji H., Koike M., Yamori T. et al. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 2001;92(5):1085–91. PMID: 11571719.
  35. Ueno T., Toi M., Saji H. et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000;6(8):3282–9. PMID: 10955814.
  36. Kacinski B.M. CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann Med 1995;27(1):79–85. PMID: 7742005.
  37. Kacinski B.M. CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Mol Reprod Dev 1997;46(1):71–4. doi: 10.1002/(SICI)1098-2795(199701)46:1<71::AIDMRD11>3.0.CO;2-6. PMID: 8981366.
  38. Lin E.Y., Gouon-Evans V., Nguyen A.V. et al. The macrophage growth factor CSF1 in mammary gland development and tumor progression. J Mammary Gland Biol Neoplasia 2002;7(2):147–62. PMID: 12465600.
  39. Smith H.O., Anderson P.S., Kuo D.Y. et al. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma. Clin Cancer Res 1995;1(3):313–25. PMID: 9815987.
  40. Lewis J.S., Landers R.J., Underwood J.C. et al. Expression of vascular endothelial growth factor by macrophages is up- regulated in poorly vascularized areas of breast carcinomas. J Pathol 2000;192(2):150–8. doi: 10.1002/1096-9896(2000)9999:9999<::AIDPATH687>3.0.CO;2-G. PMID: 11004690.
  41. Eubank T.D., Galloway M., Montague C.M. et al. M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J Immunol 2003;171(5):2637–43. PMID: 12928417.
  42. Barleon B., Sozzani S., Zhou D. et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996;87(8):3336–43. PMID: 8605350.
  43. Leek R.D., Hunt N.C., Landers R.J. et al. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol 2000;190(4):430–6. doi: 10.1002/(SICI)10969896(200003)190:4<430::AIDPATH538>3.0.CO;2-6. PMID: 10699991.
  44. Boudreau N., Myers C. Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res 2003;5(3):140–6. doi: 10.1186/bcr589. PMID: 12793895.
  45. Miles D.W., Happerfield L.C., Naylor M.S. et al. Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer 1994;56(6):777–82. PMID: 8119765.
  46. Jung Y.J., Isaacs J.S., Lee S. et al. IL-1beta-mediated up-regulation of HIF1alpha via an NFkappaB/COX-2 pathway identifies HIF1 as a critical link between inflammation and oncogenesis. FASEB J 2003;17(14):2115–7. doi: 10.1096/fj.030329fje. PMID: 12958148.
  47. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357(9255):539–45. doi: 10.1016/S0140-6736(00)04046-0. PMID: 11229684.
  48. Stacey K.J., Fowles L.F., Colman M.S. et al. Regulation of urokinase-type plasminogen activator gene transcription by macrophage colony-stimulating factor. Mol Cell Biol 1995;15(6):3430–41. PMID: 7760840.
  49. Hildenbrand R., Jansen C., Wolf G. et al. Transforming growth factor-beta stimulates urokinase expression in tumor-associated macrophages of the breast. Lab Invest 1998;78(1):59–71. PMID: 9461122.
  50. Foekens J.A., Peters H.A., Look M.P. et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000;60(3):636–43. PMID: 10676647.
  51. Hildenbrand R., Dilger I., Horlin A. et al. Urokinase and macrophages in tumour angiogenesis. Br J Cancer 1995;72(4): 818–23.
  52. Hildenbrand R., Glienke W., Magdolen V. et al. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry. Histochem Cell Biol 1998;110(1):27–32. PMID: 9681686.
  53. Fox S.B., Taylor M., Grondahl-Hansen J. et al. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. J Pathol 2001;195(2):236–43. doi: 10.1002/path.931. PMID: 11592104.
  54. Hildenbrand R., Wolf G., Bohme B. et al. Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue. J Leukoc Biol 1999;66(1):40–9. PMID: 10410988.
  55. Knoop A., Andreasen P.A., Andersen J.A. et al. Prognostic significance of urokinasetype plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 1998;77(6):932–40. PMID: 9528837.
  56. Ogmundsdottir H.M., Petursdottir I., Gudmundsdottir I. Interactions between the immune system and breast cancer. Acta Oncol 1995;34(5):647–50. PMID: 7546833.
  57. Menard S., Tagliabue E., Campiglio M., Pupa S.M. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 2000;182(2):150–62. doi: 10.1002/(SICI)1097-4652(200002)182:2<150::AIDJCP3>3.0.CO;2-E. PMID: 10623878.
  58. Nicholson S., Richard J., Sainsbury C. et al. Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 1991;63(1):146–50. PMID: 1846551.
  59. O'Sullivan C., Lewis C.E., Harris A.L., McGee J.O. Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet 1993;342(8864):148–9. PMID: 8101258.
  60. Wyckoff J.B., Segall J.E., Condeelis J.S. The collection of the motile population of cells from a living tumor. Cancer Res 2000;60(19):5401–4. PMID: 11034079.
  61. Lin E.Y., Nguyen A.V., Russell R.G., Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001;193(6): 727–40. PMID: 11257139.
  62. Arnott C.H., Scott K.A., Moore R.J. et al. Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway. Oncogene 2002;21(31):4728–38. doi: 10.1038/sj.onc.1205588. PMID: 12101411.
  63. Fischer C., Jonckx B., Mazzone M. et al. Anti-PlGF inhibits growth of VEGF(R)inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131(3): 463–75. doi: 10.1016/j.cell.2007.08.038. PMID: 17981115.
  64. Zhang W., Zhu X.D., Sun H.C. et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 2010;16(13):3420–30. doi: 10.1158/10780432.CCR-09-2904. PMID: 20570927.
  65. Wang F., Yang L., Gao Q. et al. CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion. Cancer Immunol Immunother 2015;64(8):965–76. doi: 10.1007/s00262-015-1701-9. PMID: 25944005.
  66. Andersen M.N., Abildgaard N., Maniec- ki M.B. et al. Monocyte/macrophage-de rived soluble CD163: a novel biomarker in multiple myeloma. Eur J Haemato. 2014;93(1):41–7. doi: 10.1111/ejh.12296. PMID: 24612259.
  67. Tang X. Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett 2013;332(1):3–10. doi: 10.1016/j.canlet.2013.01.024. PMID: 23348699.
  68. Adams D.L., Martin S.S., Alpaugh R.K. et al. Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci USA 2014;111(9):3514–9. doi: 10.1073/pnas.1320198111. PMID: 24550495.
  69. Forssell J., Oberg A., Henriksson M.L. et al. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 2007;13(5):1472–9. doi: 10.1158/10780432.CCR-06-2073. PMID: 17332291.
  70. Wang B., Xu D., Yu X. et al. Association of intra-tumoral infiltrating macrophages and regulatory T cells is an independent prognostic factor in gastric cancer after radical resection. Ann Surg Oncol 2011;18(9):2585–93. doi: 10.1245/s10434-011-1609-3. PMID: 21347781.
  71. Shimura S., Yang G., Ebara S. et al. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 2000;60(20):5857–61. PMID: 11059783.
  72. Robinson S.C., Scott K.A., Wilson J.L. et al. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 2003;63(23):8360–5. PMID: 14678997.
  73. Coscia M., Quaglino E., Iezzi M. et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 2010;14(12):2803–15. doi: 10.1111/j.1582-4934.2009.00926.x. PMID: 19818098.
  74. Hamilton J.A., Achuthan A. Colony stimulating factors and myeloid cell biology in health and disease. Trends Immunol 2013;34(2):81–9. doi: 10.1016/j.it.2012.08.006. PMID: 23000011.
  75. Komohara Y., Jinushi M., Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 2014;105(1):1–8. doi: 10.1111/cas.12314. PMID: 24168081.
  76. Sica A., Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012;122(3):787–95. doi: 10.1172/JCI59643. PMID: 22378047.
  77. Pello O.M., De Pizzol M., Mirolo M. et al. Role of c-Myc in alternative activation of human macrophages and tumorassociated macrophage biology. Blood 2012;119(2):411–21. doi: 10.1182/blood-2011-02-339911. PMID: 22067385.
  78. Satoh T., Takeuchi O., Vandenbon A. et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nature Immunol 2010;11(10):936–44. doi: 10.1038/ni.1920.
  79. Lawrence T., Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol 2011;11(11):750–61. doi: 10.1038/nri3088. PMID: 22025054.
  80. Germano G., Frapolli R., Belgiovine C. et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013;23(2):249–62. doi: 10.1016/j.ccr.2013.01.008. PMID: 23410977.
  81. Gabrusiewicz K., Ellert-Miklaszewska A., Lipko M. et al. Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLoS One 2011;6(8):e23902. doi: 10.1371/journal.pone.0023902. PMID: 21901144.
  82. Rogers T.L., Holen I. Tumour macrophages as potential targets of bisphosphonates. J Transl Med 2011;9:177. doi: 10.1186/14795876-9-177. PMID: 22005011.
  83. van Ginderachter J.A., Movahedi K., Van den Bossche J. et al. Macrophages, PPARs, and Cancer. PPAR Res 2008;2008:169414. doi: 10.1155/2008/169414.
  84. Lewis C., Murdoch C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol 2005;167(3):627–35. doi: 10.1016/S0002-9440(10)62038-X. PMID: 16127144.
  85. Doedens A.L., Stockmann C., Rubin- stein M.P. et al. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res 2010;70(19):7465–75. doi: 10.1158/0008-5472.CAN-10-1439. PMID: 20841473.
  86. Watkins S.K., Egilmez N.K., Suttles J. et al. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol 2007;178(3):1357–62. PMID: 17237382.
  87. Qian B.Z., Li J., Zhang H. et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011;475(7355):222–5. doi: 10.1038/nature10138. PMID: 21654748.
  88. Roland C.L., Dineen S.P., Lynn K.D. et al. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther 2009;8(7):1761–71. doi: 10.1158/1535-7163.MCT-09-0280. PMID: 19567820.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ,


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 57560 от  08.04.2014.